Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

City Therapeutics / Equity Capital Markets

<ul><li>✓ IPO Prophet Rating: 7.55/10 🏦 Deal Quality &amp; Underwriters: 8.30/10 City Therapeutics is offering 9.72 million all-primary shares at $17.00–$19.00, representing approximately $175 million at the midpoint and an implied equity valuation of roughly $906 million.</li><li>The Nasdaq transaction is expected to price October 16 under the ticker CTY.</li><li>Goldman Sachs, Jefferies, Stifel and Oppenheimer provide a strong biotechnology underwriting syndicate.</li></ul>

✓ IPO Prophet Rating: 7.55/10 🏦 Deal Quality &amp; Underwriters: 8.30/10 City Therapeutics is offering 9.72 million all-primary shares at $17.00–$19.00, representing approximately $175 million at the midpoint and an implied equity valuation of roughly $906 million.The Nasdaq transaction is expected to price October 16 under the ticker CTY.Goldman Sachs, Jefferies, Stifel and Oppenheimer provide a strong biotechnology underwriting syndicate.

<ul><li>City Therapeutics (CTY) , a Cambridge, Massachusetts-based biotechnology company, plans to list on the Nasdaq Global Market , offering 9,722,222 shares at $17–$19 per share .</li><li>At the $18 midpoint , the offering would raise approximately $175 million in gross proceeds and imply a $906 million post-offering equity valuation , based on approximately 50.3 million shares outstanding.</li><li>Goldman Sachs, Jefferies, and Stifel appear as the principal underwriters on the prospectus cover, with Oppenheimer &amp; Co. also participating.</li></ul>

City Therapeutics (CTY) , a Cambridge, Massachusetts-based biotechnology company, plans to list on the Nasdaq Global Market , offering 9,722,222 shares at $17–$19 per share .At the $18 midpoint , the offering would raise approximately $175 million in gross proceeds and imply a $906 million post-offering equity valuation , based on approximately 50.3 million shares outstanding.Goldman Sachs, Jefferies, and Stifel appear as the principal underwriters on the prospectus cover, with Oppenheimer &amp; Co. also participating.

City Therapeutics (CTY) Eyes $175 Million IPO to Advance Next-Generation RNAi Medicines

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

<ul>
<li>Early-Stage pipeline: CITY-FXI has entered early clinical development, while additional programs remain preclinical or in discovery.</li>
<li>Notable strategic validation: Collaborations with Bausch + Lomb and Biogen provide exposure to ophthalmology and central nervous system applications.</li>
<li>Demand is encouraging: Channel checks indicate the offering is well oversubscribed, supported by anchor-size conversions from mutual funds and healthcare-dedicated investors.</li>
</ul>


Early-Stage pipeline: CITY-FXI has entered early clinical development, while additional programs remain preclinical or in discovery.
Notable strategic validation: Collaborations with Bausch + Lomb and Biogen provide exposure to ophthalmology and central nervous system applications.
Demand is encouraging: Channel checks indicate the offering is well oversubscribed, supported by anchor-size conversions from mutual funds and healthcare-dedicated investors.


City Therapeutics (CTY): Big-Name Backers, Early-Stage Science and an Aftermarket Test

<ul>
<li>City Therapeutics is seeking an $856 million to $956 million valuation in an IPO, offering 9.72 million shares at $17–$19 each.</li>
<li>The RNAi-focused biotech has advanced three programs toward the clinic, backed by experienced leadership and collaborations with Bausch + Lomb and Biogen.</li>
<li>Despite strong industry validation, City remains an early-stage, pre-revenue company with limited clinical data and substantial development and funding risks.</li>
</ul>


City Therapeutics is seeking an $856 million to $956 million valuation in an IPO, offering 9.72 million shares at $17–$19 each.
The RNAi-focused biotech has advanced three programs toward the clinic, backed by experienced leadership and collaborations with Bausch + Lomb and Biogen.
Despite strong industry validation, City remains an early-stage, pre-revenue company with limited clinical data and substantial development and funding risks.


City Therapeutics (CTY): RNAi Ambitions, City Therapeutics Launches IPO With $956M Target Valuation

United States

City Therapeutics, Inc. is a biotechnology company. The Company develops RNA interference therapeutics designed to silence the expression of disease-relevant proteins for the benefit of patients in need. City Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

City Therapeutics (CTY US)

IPO Rating: City Therapeutics Inc.

✓ IPO Prophet Rating: 7.55/10 🏦 Deal Quality & Underwriters: 8.30/10 City Therapeutics is offering 9.72 million all-primary shares at...

IPO Prophet

City Therapeutics (CTY) Eyes $175 Million IPO to Advance Next-Generation RNAi Medicines

City Therapeutics (CTY) , a Cambridge, Massachusetts-based biotechnology company, plans to list on the Nasdaq Global Market , offering 9,722,222...

IPO Prophet

City Therapeutics (CTY): Big-Name Backers, Early-Stage Science and an Aftermarket Test

City Therapeutics pairs an RNAi platform with Biogen and Bausch + Lomb partnerships, but early-stage science and weak biotech IPO trading temper...

IPO Boutique

City Therapeutics (CTY): RNAi Ambitions, City Therapeutics Launches IPO With $956M Target Valuation

City Therapeutics seeks up to a $956M IPO valuation to advance RNAi medicines targeting serious diseases, leveraging an experienced team,...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)